• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Pfizer Inc. Plans $200 Million Operations Campus In Chesterfield, Missouri

One of the world’s premier biopharmaceutical companies, Pfizer Inc. will lease a new, $200 million, state-of-the-art production and operations center in Chesterfield, Missouri. The plans to create 80 jobs in the western suburb of St. Louis.

Once the new building in Chesterfield is complete, Pfizer will bring together colleagues from two sites and multiple buildings under one roof to house its bioprocess, analytical and formulation development, non-GMP processing, as well as GMP cell banking operations, and cell bank storage necessary to support both its R&D and commercial biologic and vaccine products.

“Missouri is an important part of Pfizer’s R&D network, and we’re proud of the world-class employee base we’ve built here,” said John Ludwig, Senior Vice President of BioTherapeutics Research for Pfizer. “Thanks to the support we’ve received from the state of Missouri, St. Louis County and Chesterfield, our new St. Louis laboratory facility will provide the right location and space as we continue to evolve our business over the coming years.”

Pfizer has been in Missouri for more than 13 years and currently employs more than 450 scientists and other professionals in the state. Construction is expected to begin in mid-2017 and be completed by 2020. St. Louis-based CRG together with Clayco will be the developer and owner of the new facility in Chesterfield.

To support Pfizer’s new facility, the state has offered a strategic economic incentive package that the company can receive if it meets strict job creation criteria. The expansion is also being made possible through local incentives offered by St. Louis County.

“From startups on the brink of discovery to global companies moving the needle on advanced medicine and solutions, Missouri continues to garner expansions and job creation, further solidifying its position as the epicenter of bioscience and tech innovation,” Governor Jay Nixon said. “Our education and research institutions are shaping the brightest minds that are eager to get into the lab and make a difference in the world. Companies like Pfizer benefit from this growing talent pool and the natural synergy that comes with being part of the region’s burgeoning bioscience community.”

“Pfizer is yet another example of an innovative company that has chosen St. Louis County as an important base. The company had several location options, but wanted to be here because St. Louis County is a great place to live and do business. That’s why we continue to attract businesses with diverse talent and true vision. John Ludwig and his team are at the forefront of biopharma, and they will be a true asset to our community,” said St. Louis County Executive Steve Stenger.

“Pfizer's further investment in St. Louis helps solidify the importance of the biosciences industry in the region,” said Joe Reagan, President & CEO of the St. Louis Regional Chamber. “We are very pleased to support this development that will drive further research and continue to attract top talent to our region.”

Exclusive Research